Fate Therapeutics (FATE) Misses Q3 EPS by 2c, Beats on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Fate Therapeutics (FATE) ASH Abstracts 'Underappreciated' - BMO
November 2, 2017 7:58 AM EDTBMO Capital analyst Do Kim reiterated an Outperform rating and $7 price target on Fate Therapeutics (NASDAQ: FATE) saying SITC and ASH data could driver shares.
Kim believes initial ProTmune Phase I data, released in ASH abstracts, were underappreciated, as the early results... More
